Compare Moderna, Inc. (MRNA) vs Direxion Daily TSLA Bull 2X Shares (TSLL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Direxion Daily TSLA Bull 2X Shares — how do they compare? Moderna, Inc. trades at $197.1 (market cap $78.65B), while Direxion Daily TSLA Bull 2X Shares trades at $10.33 (market cap $3.97B). The key difference: Moderna, Inc. is far larger — about 19.8× Direxion Daily TSLA Bull 2X Shares's market cap, and Moderna, Inc. is trading nearer its 52-week high, Direxion Daily TSLA Bull 2X Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Moderna, Inc. for 59 Days and Direxion Daily TSLA Bull 2X Shares for 15 Days on average.
| MRNA | TSLL | |
|---|---|---|
Market Cap | $78.65B | $3.97B |
Volume | 37,373,437 | 38,458,237 |
Sector | Health | Leveraged / Inverse |
52-Week High | $203.46 | $23.03 |
52-Week Low | $22.36 | $6.74 |
Typical Hold Time | 59 Days | 15 Days |
Enterprise Value | $74.80B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $196.48, up 4.81% with strong technical momentum as it joins the Nasdaq-100 index. Despite recent earnings beats, the company faces fundamental challenges with revenue declining from $18.9B in 2022 to $1.92B in 2025 and negative net income margins exceeding -140%. The stock's 500% rally in 2026 has pushed valuations to elevated levels with P/S ratio of 35.08, creating divergence between technical strength and financial fundamentals.
While Nasdaq inclusion and cancer vaccine pipeline progress offer catalysts, Moderna faces significant execution risks amid declining COVID revenue and high valuation multiples. Analyst consensus remains cautious with only 28% buy ratings and $115.70 price target well below current levels, suggesting limited near-term upside despite technical bullish signals.
TSLL, the Direxion Daily TSLA Bull 2X Shares ETF, trades at $10.15, down 1.55% on the day. The technical outlook is bullish based on moving averages, while oscillators are neutral. Recent news highlights its sensitivity to Tesla's performance, with a rally noted ahead of the Cybercab event. The ETF's structure amplifies daily returns, making it highly volatile and dependent on Tesla's stock movements.
The outlook for TSLL is tied directly to Tesla's stock volatility and news flow. Investment opportunities exist for traders seeking leveraged exposure to Tesla's upside, but risks include significant volatility decay and the potential for amplified losses. Investors should be cautious of the ETF's daily reset mechanism, which can lead to underperformance over time compared to holding Tesla stock directly.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Direxion Daily TSLA Bull 2X Shares
TSLL provides 200% of the daily performance of Tesla, Inc. (TSLA). It uses swaps and financial derivatives to achieve its 2x leverage, making it a high-volatility tool for tactical trading rather than long-term investment due to daily resets.
Read more on TSLL →
